After more than a year of toggling with a rebranding process, the Society of Nuclear Medicine is no more. Along with a new face, the SNM acronym and the tagline "Advancing Molecular Imaging and Therapy" are the society's brand name from now on.
After more than a year of rebranding, the Society of Nuclear Medicine is no more. Along with a new face, the SNM acronym and the tagline "Advancing Molecular Imaging and Therapy" are the society's brand name from now on.
The SNM introduced its new look, which includes a fresh logo and revamped websites for the society and the Molecular Imaging Center of Excellence, on Sunday. The move reflects the society's strategic vision to capitalize on molecular imaging's growing allure while retaining its former identity, said SNM president Dr. Martin Sandler.
A new video posted on the website notes that the SNM is altering its position to reflect changes in the way diseases are diagnosed, treated, and managed. The new strategy attempts to maintain the SNM's support of nuclear medicine while encompassing the multidisciplinary aspects of molecular imaging as well.
The SNM's new logo symbolizes the society's altered mission. (Provided by SNM)
The SNM recognized a defining moment as its mission expanded into new areas and across medical disciplines. Society members chose to continue to honor their past while moving ahead into the future, Sandler said.
"Molecular imaging is at the forefront of personalized medicine, the development of patient-specific information that allows tailored treatment of disease. SNM's look now matches its outlook and determination to spearhead the field's continued growth," he said.
Sandler also announced that the society's Bench to Bedside campaign has reached almost $4 million of its $5 million goal. The money will go to translational research designed to bridge preclinical molecular imaging and therapeutical research performed on animals and new applications for human medical care. The SNM launched the Bench to Bedside initiative at its 2006 annual meeting. A five-year timeline was set to reach the $5 million goal.
Rebranding also signals the society's intent to address the needs of practitioners and non-imaging specialists while educating members and nonmembers about the field of molecular imaging, said SNM Technologist Section president D. Scott Holbrook.
"The society will help technologists enhance their level of practice by offering programs that provide the necessary skills needed to stay current in a rapidly and technologically evolving environment," Holbrook said.
For more information from the Diagnostic Imaging archives:
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.